Quote:

---

But why would 350mg be higher than not only the entire 700mg group but also the 700mg haplotype group? ... With lower disease severity, you would of course have a smaller difference and that could be why 350mg beat 700mg. It would also explain the vast difference in chemistry and serum markers between 350mg and 700mg.

---

Exactly, I believe these 700mg patients were hardly sick at all. If anything, they only had NAS 1 or NAS 2. Hardly any had scarring. Probably none had fibrosis.
Probably none had NASH. Without out NASH, LL won't do a thing no matter how much you give.

The worse you are to start with, the more of a benefit LL will give. Amarex did not get base line cT1 or PDFF for the 700mg patients.

the haplotype group has too many, poor functioning CCR5. That's what usually happens when there is a genetic problem. The protein that is mass produced is malformed or does not work as it should. not being efficient, they probably had elevated cholesterol, triglycerides and lipids, steatosis.

When LL binded to those poorly constructed CCR5, it made them work better and so we see the strong results in reduced cT1 and reduced PDFF.